世界の非アルコール性脂肪性肝炎（NASH）市場は、2021 年に 16 億 5000 万ドルと評価されました。市場価値は、2027 年までに 150 億 4000 万ドルに達すると予測されます。非アルコール性脂肪性肝炎 (NASH) は、肝臓への過剰な脂肪蓄積 (脂肪症)、肝細胞のバルーニング、および炎症に関連する炎症性肝疾患です。非アルコール性脂肪性肝炎または「沈黙の肝臓病」は、肝臓の瘢痕化につながります。これは、アルコールの長期乱用によって引き起こされる一種の肝臓障害ですが、主に非アルコール性またはほとんどアルコールを消費しない患者で発症します。非アルコール性脂肪性肝炎 (NASH) は、肝臓の炎症と細胞損傷の段階まで進行した非アルコール性脂肪肝疾患 (NAFLD) の第 2 段階です。
医療インフラへの投資の増加、多価不飽和脂肪酸とフルクトースを含む加工食品の消費の増加、新薬の開発への関心の高まり、非侵襲的診断法の発売に携わる多くの企業などの要因が、予測期間における市場全体の成長を牽引すると予想されます。市場は、2022 年から 2027 年の予測期間中に約50%のCAGR で成長が見込まれます。
目次
1. Executive Summary
2. Introduction
2.1 Non-Alcoholic Steatohepatitis Market: An Overview
2.1.1 Definition of Non-Alcoholic Steatohepatitis (NASH)
2.1.2 Causes of Non-Alcoholic Steatohepatitis (NASH)
2.1.3 Progression of Non-Alcoholic fatty liver disease (NAFLD)
2.2 Non-Alcoholic Steatohepatitis Market (NASH) Segmentation: An Overview
2.2.1 Non-Alcoholic Steatohepatitis Market (NASH) Segmentation
3. Global Market Analysis
3.1 Global Non-Alcoholic Steatohepatitis Market: An Analysis
3.1.1 Global Non-Alcoholic Steatohepatitis Market: An Overview
3.1.2 Global Non-Alcoholic Steatohepatitis Market by Value
3.1.3 Global Non-Alcoholic Steatohepatitis Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc and Others)
3.1.4 Global Non-Alcoholic Steatohepatitis Market by Application Type (Treatment and Diagnosis)
3.1.5 Global Non-Alcoholic Steatohepatitis Market by Distribution Type (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies)
3.1.6 Global Non-Alcoholic Steatohepatitis Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Non-Alcoholic Steatohepatitis Market: Drug Type Analysis
3.2.1 Global Non-Alcoholic Steatohepatitis Market by Drug Type: An Overview
3.2.2 Global Vitamin E and Pioglitazone Non-Alcoholic Steatohepatitis Market by Value
3.2.3 Global Elafibranor Non-Alcoholic Steatohepatitis Market by Value
3.2.4 Global Ocaliva Non-Alcoholic Steatohepatitis Market by Value
3.2.5 Global Selonsertib & Cenicriviroc Non-Alcoholic Steatohepatitis Market by Value
3.2.6 Global Others Non-Alcoholic Steatohepatitis Market by Value
3.3 Global Non-Alcoholic Steatohepatitis Market: Application Type Analysis
3.3.1 Global Non-Alcoholic Steatohepatitis Market by Application Type: An Overview
3.3.2 Global Non-Alcoholic Steatohepatitis Treatment Market by Value
3.3.3 Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value
3.4 Global Non-Alcoholic Steatohepatitis Market: Distribution Type Analysis
3.4.1 Global Non-Alcoholic Steatohepatitis Market by Distribution Type: An Overview
3.4.2 Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value
3.4.3 Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value
3.4.4 Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value
4. Regional Market Analysis
4.1 North America Non-Alcoholic Steatohepatitis Market: An Analysis
4.1.1 North America Non-Alcoholic Steatohepatitis Market: An Overview
4.1.2 North America Non-Alcoholic Steatohepatitis Market by Value
4.1.3 North America Non-Alcoholic Steatohepatitis Market by Region (The US, Canada and Mexico)
4.1.4 The US Non-Alcoholic Steatohepatitis Market by Value
4.1.5 Canada Non-Alcoholic Steatohepatitis Market by Value
4.1.6 Mexico Non-Alcoholic Steatohepatitis Market by Value
4.2 Asia Pacific Non-Alcoholic Steatohepatitis Market: An Analysis
4.2.1 Asia Pacific Non-Alcoholic Steatohepatitis Market: An Overview
4.2.2 Asia Pacific Non-Alcoholic Steatohepatitis Market by Value
4.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Market by Region (China, Japan, India, Australia, South Korea and Rest of Asia Pacific)
4.2.4 China Non-Alcoholic Steatohepatitis Market by Value
4.2.5 Japan Non-Alcoholic Steatohepatitis Market by Value
4.2.6 India Non-Alcoholic Steatohepatitis Market by Value
4.2.7 Australia Non-Alcoholic Steatohepatitis Market by Value
4.2.8 South Korea Non-Alcoholic Steatohepatitis Market by Value
4.2.9 Rest of Asia Pacific Non-Alcoholic Steatohepatitis Market by Value
4.3 Europe Non-Alcoholic Steatohepatitis Market: An Analysis
4.3.1 Europe Non-Alcoholic Steatohepatitis Market: An Overview
4.3.2 Europe Non-Alcoholic Steatohepatitis Market by Value
4.3.3 Europe Non-Alcoholic Steatohepatitis Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
4.3.4 Germany Non-Alcoholic Steatohepatitis Market by Value
4.3.5 UK Non-Alcoholic Steatohepatitis Market by Value
4.3.6 France Non-Alcoholic Steatohepatitis Market by Value
4.3.7 Italy Non-Alcoholic Steatohepatitis Market by Value
4.3.8 Spain Non-Alcoholic Steatohepatitis Market by Value
4.3.9 Rest of Europe Non-Alcoholic Steatohepatitis Market by Value
4.4 Latin America Non-Alcoholic Steatohepatitis Market: An Analysis
4.4.1 Latin America Non-Alcoholic Steatohepatitis Market: An Overview
4.4.2 Latin America Non-Alcoholic Steatohepatitis Market by Value
4.5 Middle East and Africa Non-Alcoholic Steatohepatitis Market: An Analysis
4.5.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market: An Overview
4.5.2 Middle East and Africa Non-Alcoholic Steatohepatitis Market by Value
5. Impact of COVID-19
5.1 Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Market
5.2 Post COVID-19 Impact on Non-Alcoholic Steatohepatitis (NASH) Market
6. Market Dynamics
6.1 Growth Driver
6.1.1 Rising prevalence of Non-Alcoholic Steatohepatitis (NASH)
6.1.2 Rising Cases of Associated Chronic Diseases
6.1.3 Rising adoption of Sedentary Lifestyle
6.1.4 Rising Health Awareness
6.1.5 Urbanization
6.2 Challenges
6.2.1 Absence of Low Cost and Definitive Diagnostic Methods
6.2.2 Regulatory Compliance
6.3 Market Trends
6.3.1 Increasing Integration of Artificial Intelligence (AI)
6.3.2 Digitalization
6.3.3 Increased Promotion of Pipeline Drugs
6.3.4 Increasing Investment on Research and Development (R&D)
7. Competitive Landscape
7.1 Global Non-Alcoholic Steatohepatitis Market Players by Drug Development
8. Company Profiles
8.1 Intercept Pharmaceuticals, Inc.
8.1.1 Business Overview
8.1.2 Operating Geographical Region
8.1.3 Business Strategy
8.2 Novartis AG
8.2.1 Business Overview
8.2.2 Operating Segment
8.2.3 Business Strategy
8.3 Siemens Healthineers AG
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy
8.4 AstraZeneca PLC
8.4.1 Business Overview
8.4.2 Operating Geographical Region
8.4.3 Business Strategy
8.5 Galectin Therapeutics Inc.
8.5.1 Business Overview
8.5.2 Business Strategy
8.6 GENFIT S.A.
8.6.1 Business Overview
8.6.2 Business Strategy
8.7 Madrigal Pharmaceuticals, Inc.
8.7.1 Business Overview
8.7.2 Business Strategy
8.8 Inventiva S.A.
8.8.1 Business Overview
8.8.2 Business Strategy
8.9 ONE WAY LIVER, S.L. (OWL)
8.9.1 Business Overview
8.9.2 Business Strategy
8.10 Galmed Pharmaceuticals Ltd.
8.10.1 Business Overview
8.10.2 Business Strategy
8.11 Prometheus Laboratories Inc.
8.11.1 Business Overview
8.11.2 Business Strategies
8.12 BioPredictive
8.12.1 Business Overview
8.13 Cirius Therapeutics
8.13.1 Business Overview
List of Figures
Figure 1: Causes of Non-Alcoholic Steatohepatitis (NASH)
Figure 2: Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
Figure 3: Non-Alcoholic Steatohepatitis Market (NASH) Segmentation
Figure 4: Global Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Billion)
Figure 5: Global Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
Figure 6: Global Non-Alcoholic Steatohepatitis Market by Drug Type; 2021 and 2027 (Percentage, %)
Figure 7: Global Non-Alcoholic Steatohepatitis Market by Application Type; 2021 (Percentage, %)
Figure 8: Global Non-Alcoholic Steatohepatitis Market by Distribution Type; 2021 (Percentage, %)
Figure 9: Global Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
Figure 10: Global Vitamin E and Pioglitazone Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)
Figure 11: Global Elafibranor Non-Alcoholic Steatohepatitis Market by Value; 2023-2027 (US$ Billion)
Figure 12: Global Ocaliva Non-Alcoholic Steatohepatitis Market by Value; 2023-2027 (US$ Billion)
Figure 13: Global Selonsertib & Cenicriviroc Non-Alcoholic Steatohepatitis Market by Value; 2024-2027 (US$ Million)
Figure 14: Global Others Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)
Figure 15: Global Non-Alcoholic Steatohepatitis Treatment Market by Value; 2017-2021 (US$ Billion)
Figure 16: Global Non-Alcoholic Steatohepatitis Treatment Market by Value; 2022-2027 (US$ Billion)
Figure 17: Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value; 2017-2021 (US$ Million)
Figure 18: Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value; 2022-2027 (US$ Million)
Figure 19: Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
Figure 20: Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
Figure 21: Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
Figure 22: Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
Figure 23: Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
Figure 24: Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
Figure 25: North America Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
Figure 26: North America Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
Figure 27: North America Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
Figure 28:The US Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)
Figure 29: Canada Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 30: Mexico Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 31: Asia Pacific Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
Figure 32: Asia Pacific Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
Figure 33: Asia Pacific Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
Figure 34: China Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 35: Japan Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 36: India Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 37: Australia Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 38: South Korea Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 39: Rest of Asia Pacific Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 40: Europe Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
Figure 41: Europe Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
Figure 42: Europe Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
Figure 43: Germany Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 44: UK Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 45: France Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 46: Italy Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 47: Spain Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 48: Rest of Europe Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
Figure 49: Latin America Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
Figure 50: Latin America Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
Figure 51: Middle East and Africa Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
Figure 52: Middle East and Africa Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
Figure 53: NASH Prevalence, Diagnosed and Treated Cases; 2021 & 2030 (Million)
Figure 54: Global Number of People with Diabetes; 2021-2027 (Million)
Figure 55: Global Number of People with Obesity; 2020-2030 (Million)
Figure 56: Global Artificial Intelligence Market Size; 2021-2025 (US$ Billion)
Figure 57: Intercept Pharmaceuticals, Inc. Net Product Revenue by Geographical Region; 2021 (Percentage, %)
Figure 58: Novartis AG Net Sales by Reportable Segments; 2021 (Percentage, %)
Figure 59: Siemens Healthineers AG Revenue by Segments; 2022 (Percentage, %)
Figure 60: AstraZeneca PLC Revenue by Geographical Region; 2021 (Percentage, %)
Table 1: Global Non-Alcoholic Steatohepatitis Market Players by Drug Development
